Kazia Therapeutics has initiated a registered public offering of American Depositary Shares and warrants to raise funds primarily for clinical development of its cancer drug paxalisib. The offering includes Series A and B warrants exercisable upon key clinical data readouts expected in 2027 and 2028. Proceeds will support ongoing trials in triple-negative and HR+/HER2- breast cancers, among other oncology indications. The offering is managed by Leerink Partners and Guggenheim Securities and is subject to market conditions.
Clearfield cut its FY2026 guidance because of delays in broadband projects linked to slow government BEAD program rollout and fiber supply constraints. However, the company secured a $22 million order for hyperscale data centers, validating its growt...
Cardano's ADA price fell over 7% to around $0.210, dipping below $0.220 despite large wallets buying 160 million tokens during the decline. Market sentiment is bearish with a low long-to-short ratio of 0.74, though some bullish signs appear in positi...
System1 Group has again rejected Brave Bison's takeover offer, citing that the terms remain unchanged and the offer undervalues System1's shares. Brave Bison's proposal values System1 shares at a discount of 8.2% to the current market price, which Sy...
Bitcoin's price has stalled around $80,000, causing Strategy Inc.'s (MSTR) market value to net asset value (mNAV) premium to shrink near 0.74x, erasing its previous advantage. Strategy holds over 840,000 BTC but faces about $1.5 billion in annual pre...
An analyst initiates coverage of Sezzle with a strong buy rating and a price target of $169 per share, citing key growth drivers such as subscriber growth, increased purchase frequency, new products like SezzleCash and Sezzle Send, enterprise merchan...
